# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stephens & Co. analyst Sudan Loganathan initiates coverage on Exelixis (NASDAQ:EXEL) with a Equal-Weight rating and anno...
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $28 price target.
TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $25 to $27.
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.24 by 2...
Barclays analyst Peter Lawson downgrades Exelixis (NASDAQ:EXEL) from Overweight to Equal-Weight and maintains the price targ...